期刊文献+

慢性阻塞性肺疾病患者血清中IL-32、8-iso-PGF2α的变化及意义 被引量:14

Serum change and significance of IL-32,8-iso-PGF2α in chronic obstructive pulmonary disease
下载PDF
导出
摘要 目的:通过测定慢性阻塞性肺疾病(COPD)患者血清中IL-32、8-iso-PGF2α水平,观察其在COPD不同时期中的变化及临床意义。方法:随机选取40例COPD患者,40例健康体检者作为对照组,通过酶联免疫法测定AECOPD、稳定期及健康对照组血清中IL-32及8-iso-PGF2α变化水平。结果:检测者血清中IL-32、8-iso-PGF2α水平健康对照组、COPD稳定期、AECOPD患者三组数据呈现逐渐增高趋势,即急性加重期高于稳定期,稳定期高于对照组。结论:血清中IL-32及8-iso-PGF2α在COPD的动态变化参数,为判断该疾病严重程度,并为临床治疗、评估治疗效果及出院后是否继续治疗提供理论依据。 Objective: To observe the changes and clinical significance in different periods of COPD through the determination of patients with chronic obstructive pulmonary disease (COPD) in serum IL - 32 and 8 - iso - PGF2 alpha level. Methods: We selected 40 cases of hospitalized patients with COPD and 40 healthy sub- jects as controls. We used enzyme-linked immunosorbent to assay the changes of serum IL-32 and 8-iso- PGF2a levels in AECOPD, stable and healthy controls. Results: The data of serum IL-32 and 8-iso- PGF2a levels in healthy controls, COPD stable, AECOPD patients showed a gradual increasing trend, that is, the data in acute exacerbation is higher than that in stable, and data in stable is higher than that in controls. Conclusion: The dynamic changes parameters of Serum IL-32 and 8-iso-PGF2a in COPD provide a theo- retical basis for judging the severity of the disease, and for clinical treatment, treatment effects assess and whether to continue treatment after discharge.
出处 《黑龙江医药科学》 2014年第2期6-7,共2页 Heilongjiang Medicine and Pharmacy
关键词 慢性阻塞性肺疾病 白介素32 8-异前列腺素 酶联免疫法 chronic obstructive pulmonary disease IL- 32 8 - iso - PGF2a enzyme - linked im- munosorbent assay
  • 相关文献

参考文献11

  • 1刘永翠,马雪梅.特布他林联合布地奈德雾化吸入治疗COPD急性加重期的临床效果与护理[J].黑龙江医药科学,2010,33(1):52-53. 被引量:18
  • 2Global strategy for the diagnosis, management, and Prevention of chronic obstruetive pulmonary disease. NHLBI/WHO workshop report. Update, 2003.
  • 3武焱旻.舒利迭粉吸入剂对Ⅲ-Ⅳ级慢性阻塞性肺病患者肺功能的影响[J].黑龙江医药科学,2006,29(6):32-33. 被引量:10
  • 4Baraldo S, Turato G. Neutrophili infiltration within the airway smooth muscle in Patients with COPD [J 3. Thorax, 2004,59 (4) : 308-312.
  • 5Kim SH, Han SY, Azam T, et al. Interieukin--32s a cytokine and inducer of TNFalpha[J]. Immunity, 2005, 22(1) :131-142.
  • 6Kim SH, Han SY. Interleukin--32z a cytokine and inducer of TNF alpha[J]. Immunity, 2005,22 (1) : 131-142.
  • 7Calabrese F, Baraldo S,Bazzan E, et al. IL--32, a novelpro--in- flammatory cytokine in chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Mecl, 2008, 178(9) :894-901.
  • 8Joosten Leo AB, Netea MG, Kim SH, et al. IL --32, a pro--in- flammatory eytokine in rheumatoid arthritis [J]. USA Proc Natl Acad Sci, 2006,103 (9): 3298-3303.
  • 9Wei L, Yah L, Muhammad MM, et al. Activation of Interleukin --32 Pro--Inflammatory Pathway in Response to Influenza A Virus Infeetion[J]. PLOS ONE, 2008,3(4):1-9.
  • 10FukunagaM, YuraT, Grygorczyk R,et al. Evidence for the dis- tinct nature of F2--isoProstane receptors from those of thrombox- ane A2[J]. Am J Physiol,1997,272:477-483.

二级参考文献10

共引文献26

同被引文献144

引证文献14

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部